Introduction {#S1}
============

American Indians have a high prevalence of obesity, type 2 diabetes (T2D) and metabolic syndrome. ^[@R1],\ [@R2]^ These conditions, together with hypertension, hyperlipidemia ^[@R3],\ [@R4]^ and smoking ^[@R5],\ [@R6]^ may contribute to an increased burden of chronic kidney disease (CKD), defined either by increased albuminuria or by decreased glomerular filtration rate (GFR).^[@R7]-[@R9]^ CKD is associated with increased cardiovascular disease events and death in American Indians. ^[@R10],\ [@R11]^ Therefore, understanding the pathways leading to CKD is relevant to public health.

T2D is one of the most common conditions associated with CKD and kidney failure in Western populations. ^[@R12]^ Diabetic nephropathy most typically progresses through an early phase in which microalbuminuria, detected by a spot urine albumin to creatinine ratio (UACR) ≥ 30 mg/g, is associated with supranormal glomerular filtration rate (GFR), i.e., glomerular hyperfiltration ^[@R13]-[@R15]^. These initial abnormalities may be reversible but then may progress to macroalbuminuria (UACR ≥300 mg/g) and an irreversible decline in GFR. Alternatively, in some T2D individuals, impaired GFR can occur without substantial albuminuria. ^[@R16]^ In the Strong Heart Study (SHS), American Indians with T2D often have micro or macroalbuminuria associated with decreased GFR. ^[@R17]^ Similarly, young Pima Indians with T2D, aged 5 to 19 years, frequently have microalbuminuria which is a strong predictor of macroalbuminuria at follow up. ^[@R18]^

Diabetic nephropathy occurs more often among family members ^[@R19]^ suggesting a genetic susceptibility to this complication. The heritability of kidney traits in American Indians has been documented for estimated GFR (eGFR) and UACR, a marker of kidney damage. ^[@R20]-[@R23]^ Genome-wide association studies (GWAS) have identified several loci associated with T2D (reviewed in ^[@R24]^). There is some evidence for associations of T2D loci with diabetic nephropathy including reported variants in *PPARG* in Chinese ^[@R25]^ and *KCNQ1* in Japanese individuals. ^[@R26]^ In addition, *TCF7L2* has been associated with diabetic nephropathy in individuals with early onset T2D ^[@R27]^ and among middle-aged individuals. ^[@R28]^ Given the large number of newly identified loci for T2D, the effects of genes associated with T2D on kidney function and damage merit exploration in American Indian populations.

We recently genotyped several GWAS validated single nucleotide polymorphisms (SNPs) in American Indians in the Genetic Epidemiology of Causal Variants Across the Life Course (CALiCo) Consortium as part of the Population Architecture using Genomics and Epidemiology (PAGE) study. ^[@R29]^ We describe associations of T2D SNPs with prevalent eGFR and UACR in over 6,900 American Indians from the Strong Heart Family Study (SHFS) and SHS cohort. We also explored the evidence for SNP associations with incident CKD and new-onset microalbuminuria using longitudinal data from the SHS participants.

Results {#S2}
=======

Baseline characteristics of the SHFS and SHS cohort American Indian samples are displayed in [Table 1](#T1){ref-type="table"}. By design, the mean age of SHFS participants was lower than that of the SHS cohort participants. The prevalence of T2D and impaired fasting glucose varied across centers but the mean body mass index (BMI) was similar when comparing cohort to family members for a same recruiting center. Cohort participants had lower mean eGFR and higher median UACR than family study participants. Eighteen SNPs representing 15 loci were examined. Minor allele frequencies (MAF) per center are shown in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. Two SNPs in each the *FTO* and the *TCF7L2* genes were highly correlated in American Indians (r^2^\>0.95 in the overall sample and within each center).

Cross-sectional associations with eGFR and UACR in the SHS and SHFS samples {#S3}
---------------------------------------------------------------------------

We identified significant associations of SNPs in *FTO, TCF7L2,* and *KCNJ11* with eGFR (p\<0.003) ([Table 2](#T2){ref-type="table"}). The *FTO* rs8050136 A allele and *TCF7L2* rs7901695 C allele (both associated with increased risk of T2D) were associated with a 0.08 and 0.09 reduction of eGFR residuals per allele copy, respectively. The *KCNJ11* rs5219 T allele, previously associated with increased T2D risk, was associated with 0.05 reductions in eGFR residuals per allele copy. We also identified nominal associations of *WFS1* with eGFR and UACR. The *WFS1* rs10010131 G allele was associated with increased eGFR and UACR but we noted a significant between study heterogeneity for the association with eGFR (p for heterogeneity=0.07). In center-specific analyses, we noted the lowest p-values in analyses of the SHFS compared to the older (\>45 years) SHS participants ([Table 2](#T2){ref-type="table"} footnote). We thus hypothesized age-specific effects on eGFR. We then performed analyses using age categories (\<45, 45 to 59 and 60 years or more). The magnitude of effect of *WFS1* rs10010131 G allele on eGFR was larger in American Indians \<45 years-old (p=0.0003) compared to those 45 to 59 or ≥60 years, in whom the SNP effect was greatly attenuated ([Figure 1](#F1){ref-type="fig"}, [Supplemental Table 2](#SD1){ref-type="supplementary-material"}, p for heterogeneity=0.05, I^2^ = 67.5%).

To examine if these effects were mediated by diabetes, we also performed diabetes-stratified analyses ([Supplemental Table 3](#SD1){ref-type="supplementary-material"}) and analyses adjusting for T2D. Interestingly, *TCF7L2* SNP association with eGFR was unchanged when adjusting for T2D. The overall T2D-adjusted associations of *WFS1(*p=0.08), *KCNJ11* (p=0.72) and *FTO* (p=0.03) with eGFR were no longer significant but the age-specific association with eGFR for the *WFS1*SNP was mostly unchanged (p=0.0003 to 0.0008, n=2249, for association among individuals 45 years or younger). The association of rs10010131 with UACR was no longer significant when adjusting for T2D.

Longitudinal associations with CKD and microalbuminuria in the SHS cohort {#S4}
-------------------------------------------------------------------------

In prospective data of SHS participants, incident (stage 3) CKD events were defined by the new occurrence of an eGFR of 60 ml/min/1.73 m^2^ or lower, or by self-report of maintenance dialysis or kidney transplantation among individuals with eGFR \> 60 ml/min/1.73 m^2^. Approximately 477 CKD events occurred among 3,160 individuals at a median follow-up of 8 years. Of the 3,918 SHS participants with baseline eGFR ≥ 60 ml/min/1.73 m^2^, 1,035 with albuminuria at baseline were excluded for the analysis of incident albuminuria (approximately 499 events). A *FTO* SNP (rs9939609) was significantly associated with incident CKD in the Dakotas but not in the analyses of all three centers ([Supplemental Table 4](#SD1){ref-type="supplementary-material"}) and none of the loci was associated with new-onset microalbuminuria ([Supplemental Table 5](#SD1){ref-type="supplementary-material"}). However, the direction of the effect of the association with microalbuminuria was consistent with the findings for continuous UACR.

Discussion {#S5}
==========

CKD affects minorities disproportionally, who also progress more often to end-stage renal disease (ESRD) than individuals of European ancestry. ^[@R8],\ [@R9]^ American Indians have a high prevalence of obesity and T2D, which contribute to the large burden of cardiovascular and kidney diseases in this population. ^[@R7]-[@R9],\ [@R30]^ We investigated the genetic contribution of recently discovered T2D genetic variants to kidney function and markers of kidney damage in American Indians. The selected SNPs were initially identified in European and Asian ancestry studies and some of these variants have also been replicated for T2D associations in American Indian participants of the SHS (Haiman et al., Diabetes, under review). Several loci (*FTO*, *KCNJ11, TCF7L2* and *WFS1*) were associated with eGFR and a SNP in *WFS1* was associated with albuminuria. *WFS1* product is a transmembrane protein localized to the endoplasmic reticulum (ER) ^[@R31]^ which is involved in ER stress signaling pathways. ^[@R32]^ The *WFS1* SNP T2D risk allele was associated with increased albuminuria and eGFR, with a large effect on eGFR in American Indians younger than 45 years-old compared to those 45 to 59 years or older than 60 years, for whom the SNP effect was greatly attenuated. In analyses adjusted for both BMI and T2D, the association with eGFR was slightly changed in the younger age category but was no longer significant for UACR. These are interesting findings as American Indians develop diabetic nephropathy at earlier ages than individuals of other ancestry. ^[@R33]^ Early stages in the pathogenesis of the diabetic nephropathy are characterized by microalbuminuria and hyperfiltration. Our findings of increasing eGFR and albuminuria for *WFS1*, although modest, are consistent with the early development of nephropathy and suggest that the genetic effect is partially mediated by diabetes. Our findings will require further confirmation in American Indians and other populations, and in studies using direct measures of kidney function to detect higher ranges of GFR.

In contrast, the alleles associated with T2D risk for *FTO*, *KCNJ11, TCF7L2* were associated with reduced eGFR in American Indians and were not associated with albuminuria. *FTO* is known to confer risk for T2D through its association with obesity ^[@R34]^ in both children and adults. ^[@R34],\ [@R35]^ Variants in this gene have been recently reported to be associated with end-stage renal disease in two case-control studies ^[@R36]^. Of interest, the associations with low eGFR in American Indians occurred in models adjusting for BMI suggesting an effect independent of body size, although the mean BMI in American Indians in our study was high and in the range of overweight to obese. The *KCNJ11* gene was identified in T2D associations in individuals of European and Asian ancestry. ^[@R37]-[@R39]^ It impairs glucose-induced insulin release and it has also been associated with increased BMI ^[@R40],\ [@R41]^. It is intriguing that variants in both these loci are associated with lower eGFR in the context of obesity, which is a risk factor for CKD. ^[@R42]^ However, for both loci, the associations seem to be mediated by diabetes as they are no longer significant in analyses adjusted for T2D.

*TCF7L2* has shown consistent associations with T2D across ancestry groups ^[@R43],\ [@R44]^ and, in American Indians, it has been associated with glucose homeostasis traits (unpublished data). TCF7L2 is a key component of the *Wnt* signaling pathway involved in the regulation of pancreatic beta-cell proliferation, differentiation and insulin secretion ^[@R45]^ but also important in kidney embryogenesis and disease. ^[@R46]^ The rs7903146 T allele was significantly associated with lower eGFR in American Indians but not with incident CKD in contrast to a previous report in a population-based study of middle-aged individuals. ^[@R28]^ Interestingly, a recent large study of T2D showed association of the rs7903146 T allele with diabetic nephropathy, with larger effect in individuals with early onset T2D.^[@R27]^ In our study, this genetic variant shows no evidence of heterogeneity across age categories. In addition, the association was slightly attenuated when adjusting for diabetes. Therefore, our findings suggest that at least four T2D loci are associated with kidney traits in American Indians of which two may have effects that are partially independent of diabetes. These findings may have important implications in prevention efforts for CKD in this population.

Our prospective associations with incident CKD and new onset-albuminuria were restricted to the SHS cohort study which has long-term longitudinal data. Although we noted significant associations for the *FTO* rs9939609 A allele in the Dakotas, our samples were limited. In addition, we did not identify associations with new-onset albuminuria for tested SNPs.

This study used kidney function estimates from an equation derived from CKD individuals. Calibrated serum creatinine concentrations are currently not available in the SHS. The SNPs investigated were identified in individuals of European ancestry. However, the *FTO*, *WFS1* and *TCF7L2* SNPs associations have replicated in American Indians for T2D or glycemic traits.

In summary, we identified four T2D loci associated with kidney function in American Indians including two previously reported associations with kidney traits in individuals of European ancestry. The *WFS1* variant was associated with increased albuminuria and eGFR and it showed age-specific effects on eGFR. These findings suggest shared genetic risk factors for T2D and its kidney complications in this population.

Concise Methods {#S6}
===============

Population and phenotypes {#S7}
-------------------------

The SHS is a population-based cohort study funded by the National Heart, Lung, and Blood Institute (NHLBI) of 4,549 American Indian men and women, ages 45-74 years and recruited from 13 tribes located in Arizona, North and South Dakota, and Oklahoma, who underwent a baseline (1989-1991) and then two follow-up (1993-1995 and 1996-1999) examinations. ^[@R47]^ The SHFS started in 1998 to study the genetics of cardiovascular disease among American Indian populations and it recruited family members from the original cohort study. ^[@R48]^ Over 3,600 American Indians aged 14 to 93 years and in 94 multigenerational families were examined, of whom 540 also are SHS cohort members (and were included in the family data only for analyses). The SHS and SHFS protocols were approved by the Indian Health Service Institutional Review Board, by the Institutional Review Boards of the participating Institutions, and by the Indian tribes participating in these studies. ^[@R47],\ [@R48]^ All participants gave informed consent for genetic testing.

Demographic data and medical history were obtained by a personal interview during a clinical exam. Anthropometric measures of body weight (kg) and height (m) were used to estimate BMI (kg/m^2^). Blood was collected after an overnight fast and plasma or serum samples were stored at −80°C until analyzed. T2D was defined as a fasting blood glucose of 126 mg/dl or higher, history of diabetes or use of diabetic medications. ^[@R49]^ Impaired fasting glucose and impaired glucose tolerance were defined by the World Health Organization criteria based on fasting plasma glucose and 75 gram oral glucose tolerance test results. Serum and urine creatinine were assayed by a kinetic alkaline picrate method and urine albumin by a sensitive nephelometric method, both on the Hitachi 717 platform (Roche Diagnostics, Indianapolis, IN). Urine albumin excretion was estimated as the UACR (mg/g) and eGFR was calculated using the Modified Diet and Renal Disease (MDRD) equation. ^[@R50]^

In prospective data of SHS participants, incident (stage 3) CKD events were defined by the new occurrence of an eGFR of 60 ml/min/1.73 m^2^ or lower, or by self-report of maintenance dialysis or kidney transplantation. CKD events included events that occurred during a median of 8 years follow-up between the baseline and visit 3 examinations in those individuals without a prior history of CKD (n=516 with CKD at baseline were excluded). New onset albuminuria was defined either as: 1. UACR ≥ 30 mg/g at follow-up among individuals with UACR\< 30 mg/g at baseline or as 2. UACR ≥ 30 mg/g at follow-up among individuals with UACR\< 30 mg/g at baseline and with a baseline eGFR ≥60 ml/min/1.73 m^2^. Of 4,549 SHS participants, 1,035 with albuminuria at baseline were excluded for the analysis of incident albuminuria by definition 1. Of 3,918 SHS participants with baseline eGFR ≥ 60 ml/min/1.73 m^2^, 1,313 with albuminuria at baseline were excluded for the incident albuminuria defined by definition 2. Because results were unchanged using definition 1 or 2, we reported only findings using definition 1.

SNP selection, genotyping and quality control {#S8}
---------------------------------------------

SNPs were selected from T2D GWAS publications prior to January 2009 and our analysis is thus restricted to these loci. Genotyping was performed at the University of Texas Health Science Center -- Houston using Taqman assays (Applied Biosystems). Replica samples were included as controls. Quality control performed included sample call rates (\>95%), concordance of blinded replicates (\>98%), and deviation from Hardy-Weinberg equilibrium among founders (p\<0.01). Individuals with more than 10% of missing genotypes (n=64) were excluded. Eighteen SNPs on 15 loci passed quality control and were included in these analyses ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). SNPs that failed genotyping were rs4430796 (*HNF1b*), rs2074196 (*KCNQ1*) and rs1326634 (*SLC30A8*). We estimated the linkage disequilibrium between SNPs in the same loci using Haploview.

Statistical Analysis {#S9}
====================

Cross-sectional analyses {#S10}
------------------------

Quantitative traits with non-normal distribution were natural log-transformed for analysis. We obtained center-specific residuals of eGFR and log UACR (LACR) using linear regression models adjusted for age, age^2^, sex, age and sex interactions and BMI. These residuals were then regressed onto SNP dosage using variance component models for family data to account for family relatedness and population history ^[@R51]^ and using linear regression for analysis of unrelated individuals (SHS). For SHS analyses, we also adjusted for self-reported blood quantum to account for ancestry. To account for age-specific effects, analyses were performed within categories of age (\<45, 45 to 59 and 60 or older). We performed a quantitative transmission disequilibrium test ^[@R52]^ in the SHFS and found no evidence of population substructure within centers but significant evidence of population stratification when combining centers. Therefore analyses were stratified by center.

Summary estimates were combined across age-categories and centers using a weighted average of point estimates meta-analyses. We also tested for evidence of between-study heterogeneity ^[@R53]^ for age- and center-estimates by estimating the between-study variance and the I^2^ metric, which is a measure of the percentage of the total variation across strata due to heterogeneity rather than chance ^[@R54]^. Unadjusted p-values are reported. A Bonferroni correction for multiple testing p=0.003 (α=0.05/15 independent tests) was considered significant. In sensitivity analyses, we excluded 333 individuals younger than 18 years (range 15 to 17) from eGFR analyses and age-specific results were unchanged. We also performed analyses adjusting for T2D and stratified analyses by diabetes.

Longitudinal analyses {#S11}
---------------------

For significant SNP associations in cross-sectional analysis, we evaluated associations with incident CKD and increased albuminuria in the SHS using center-stratified logistic regression models adjusted for age, age^[@R2]^, sex and BMI. Odds ratio (OR) and 95% confidence intervals (CI) are reported. A Bonferroni correction for multiple testing p=0.01 (α=0.05/4 independent tests) was considered significant.
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![Age-specific effects of *WFS1* rs1001013 G allele on eGFR residuals. Numbers are 2249, 2996 and 1587 for age\<45, 45 to 59 and 60 years or older.](nihms363695f1){#F1}

###### Baseline characteristics of American Indians of the Strong Heart Family Study (1998-2003) and Strong Heart Study (1989-1991)

                                                                     Strong Heart Family Study   Strong Heart Study                                                               
  ------------------------------------------------------------------ --------------------------- -------------------- ------------------- ----------------- --------------------- ---------------------
  Number                                                             1176                        1165                 1167                1188              1147                  1115
  Mean age (SD), years                                               38.4 (16.8)                 36.2 (15.5)          43.4 (17.3)         56.3 (8.1)        55.8 (7.9)            56.8 (8.4)
  Female sex %                                                       58.7                        62.1                 59.3                56.8              63.8                  57.9
  Type 2 diabetes %                                                  13.4                        31.4                 19.8                33.1              63.7                  36.1
  Impaired fasting glucose %                                         7.9                         8.1                  6.2                 14.7              10.7                  14.5
  Mean BMI (SD), kg/m^2^                                             30.1 (6.8)                  35.5 (8.8)           31.1 (6.9)          29.3 (5.5)        32.5 (7.1)            30.7 (6.0)
  Mean eGFR (SD), ml/min/1.73 m^2^[\*](#TFN2){ref-type="table-fn"}   96.6 (23.8)                 114.5 (28.9)         93.6 (22.9)         81.3 (20.3)       86.1 (23.6)           78.6 (17.5)
  Median UACR (25-75%), mg/g                                         7.1 (1.7-7,805.9)           10.4 (1.7-9,756.1)   7.1 (1.1-9,645.7)   7.5 (0.1-7,493)   27.1 (0.1-65,000.0)   8.5 (0.04-12,419.8)

SD, standard deviation; BMI, body mass index; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio.

eGFR was estimated using the MDRD equation

###### Meta-analyses findings for type 2 diabetes-SNP associations for eGFR and log UACR residuals

  Trait   SNP                                         Loci/gene   Coded Allele   Other Allele   β         SE       P-value   Number   P-value for heterogeneity   Direction of effect for coded allele
  ------- ------------------------------------------- ----------- -------------- -------------- --------- -------- --------- -------- --------------------------- --------------------------------------
  eGFR    rs8050136[\*](#TFN4){ref-type="table-fn"}   *FTO*       A              C              -0.078    0.0253   0.002     6835     0.13                        ↑BMI and T2D
          rs9939609[\*](#TFN4){ref-type="table-fn"}   *FTO*       A              T              -0.0751   0.0252   0.003     6802     0.18                        ↑BMI and T2D
          rs5219                                      *KCNJ11*    T              C              -0.0543   0.0178   0.002     6807     0.91                        ↑T2D
          rs7901695[\*](#TFN4){ref-type="table-fn"}   *TCF7L2*    C              T              -0.0884   0.0265   0.0008    6834     0.24                        ↑T2D
          rs7903146[\*](#TFN4){ref-type="table-fn"}   *TCF7L2*    T              C              -0.0758   0.0269   0.005     6837     0.17                        ↑T2D
          rs10010131[†](#TFN5){ref-type="table-fn"}   *WFS1*      G              A              0.0704    0.0252   0.005     6837     0.07                        ↑T2D
  UACR                                                                                                                                                            
          rs10010131                                  *WFS1*      G              A              0.0684    0.0263   0.009     6784     0.34                        ↑T2D

SNP, single nucelotide polymorphism; SE, standard deviation; eGFR, estimated glomerular filtration rate; log UACR (urine albumin-to-creatinine ratio); T2D, type 2 diabetes

*FTO* variants (rs8050136 and rs9939609) and *TCF7L2* variants (rs7901695 and rs7903146) are in linkage disequilibrium: r^2^\>0.95 in the overall sample and within each center.

Estimates for the family study are: beta (se) = 0.12 (0.04), p=0.0008) and for cohort study beta (se) = -0.02 (0.04), p=0.63.
